DCGO logo

Docgo Inc (DCGO)$0.63

Market Cap: 232.90 MCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Docgo Inc (DCGO).

HEALTHCARE
MEDICAL CARE FACILITIES
DCF ready

Valuation

6.1x

EV/FCF, 16.4% FCF yield

Quality

-136.1%

ROIC, 9.3% FCF margin

Growth

27.9%

5Y sales (revenue) CAGR

Balance sheet

0.0x

Debt/equity, 2.3x current ratio

Superinvestors

1

Top: David Katz (0.0%)

Strengths to research

  • Revenue compounded at 27.9% over five years.
  • Debt/equity looks manageable at 0.0x.

Watchouts

No major valuation, balance sheet, or growth watchouts were detected by the static screen.

Annual data: 6 periods
Quarterly data: 21 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for DCGO.

Grade D
31
/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best
DCGO
Target
Docgo Inc$232.9M-0.3x6.1x-136.1%27.9%9.3%N/AN/AN/A
INBXInhibrx$178.5M-11.2x-0.4x-1752.2%N/A-9986.5%N/AN/AN/A
DMACDiaMedica Therapeutics Inc.$171.4MN/A-5.4x-58.4%N/AN/AN/AN/AN/A
DNAGinkgo Bioworks Holdings Inc.$402.4M-1.5x-1.3x-0.1%17.3%-105.0%N/AN/AN/A
ORICORIC Pharmaceuticals Inc.$405.2M-5.7x-3.2x-33.7%N/AN/AN/AN/AN/A
CGENCompugen Ltd$128.1M7.4x1.2x34.4%105.2%43.1%87.3%-2.8xN/A
LABStandard Biotools Inc$435.8M-5.1x-3.8x-17.7%-9.2%-96.9%49.9%N/AN/A
PGENPrecigen Inc.$448.7M-3.1x-5.7x-219.7%-21.3%-927.6%N/AN/AN/A
COYACoya Therapeutics Inc$107.2M-3.8x-5.6x-49.3%N/A-135.2%N/AN/AN/A

Financial Charts

No financial data available for DCGO (annual).

1 superinvestors own DCGO

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership
FundSharesValue% PortfolioQoQ Change
David Katz

Matrix Asset Advisors

100,000$63,0000.01%0.0%